X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ORMD-0801 (oral insulin) capsule, with enhanced patient compliance, is currently undergoing phase III clinical trials for the T2DM indication. Drug has the potential to delay the disease progression or even eliminating late-stage complications.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Hefei Tianmai Biotechnology Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
ORMD-0801 (oral insulin) Capsule, with enhanced patient compliance, is currently undergoing phase III clinical trials for the T2DM indication. Drug has the potential to delay the disease progression or even eliminating late-stage complications.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
ORMD-0801 (Oral insulin) Capsule, with enhanced patient compliance, is currently undergoing phase III clinical trials for the T2DM indication. Drug has the potential to delay the disease progression or even eliminating late-stage complications.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Article presents results of 12-week multicenter, randomized, placebo-controlled trial assessing safety and efficacy of multiple active doses of ORMD-0801 in patients with T2DM on chronic background therapy with Metformin or combination oral therapy.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
The trial demonstrated that ORMD-0801, an oral insulin candidate, was safe and well tolerated at 8 mg twice daily dosing, meeting the primary endpoint of no difference in adverse events for ORMD-0801 compared to placebo.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
The agreement grants Medicox an exclusive license to apply for regulatory approval for and distribute Oramed's oral insulin candidate, ORMD-0801, for ten years in the Republic of Korea.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Medicox Co.
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022
Details:
Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 trials and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
Oravax's oral Covid-19 vaccine candidate is designed using D-Crypt™ technology as a triple antigen VLP vaccine that targets three major surface proteins of the SARS-CoV-2 virus - Spike, Membrane and Envelope.
Lead Product(s): Triple Antigen VLP Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
The 12-week trial enrolled 32 patients (with 30 patients completing) and demonstrated that ORMD-0801 (insulin) was safe and well tolerated at 8 mg twice daily dosing, meeting the primary endpoint of no difference in adverse events for ORMD-0801 compared to placebo.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Primary endpoint of trial is to compare efficacy of ORMD-0801 (Insulin) to placebo in improving glycemic control by A1c over a 26-week treatment period, with a secondary endpoint of comparing ORMD-0801 to placebo in maintaining glycemic control over a 52-week treatment period.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
